We are live on ! Find out more
ALLR

Allarity Therapeutics
ALLR

4 hedge funds and large institutions have $46.2K invested in Allarity Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.49% more ownership

Funds ownership: 0% → 0.49% (+0.49%)

56% less funds holding

Funds holding: 9 → 4 (-5)

57% less capital invested

Capital invested by funds: $108K → $46.2K (-$61.6K)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
4
Holders Change
-5
Holders Change %
-55.56%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$80.2K
2
TRCT
Tower Research Capital (TRC)
New York
+$14.1K
3
DB
Danske Bank
Denmark
+$38
4
Bank of America
Bank of America
North Carolina
+$28

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$56K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$21.8K
3
JF
Jump Financial
Illinois
-$8.26K
4
HF
HRT Financial
New York
-$7K
5
Jane Street
Jane Street
New York
-$3.33K

ALLR Hedge Fund Activity: Q3 2024 in Review

4 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q3 2024, worth a combined $46.2K — down 57% from $108K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ALLR and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was UBS Group, adding an estimated $80.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $56K sold.

  • 4 institutional investors held Allarity Therapeutics (ALLR) as of Q3 2024, down from 9 in Q2 2024.
  • Funds reported $46.2K of Allarity Therapeutics stock for Q3 2024, down 57% quarter-over-quarter.
  • 1 fund opened new Allarity Therapeutics positions in Q3 2024 and 6 closed out, a net change of -5 holders.
  • The largest Allarity Therapeutics buyer in Q3 2024 was UBS Group, an estimated $80.2K added.
  • The largest Allarity Therapeutics seller in Q3 2024 was Virtu Financial, an estimated $56K sold.

Based on aggregated 13F filings for Q3 2024.